EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study

Emmanuel Gonzalez-Bautista iD, Maria Soto, Gabor Abellan van Kan iD, Julien Delrieu

GeroScience · 2025

DOI: 10.1007/s11357-024-01497-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift GeroScience, 2025. Verfasst von Emmanuel Gonzalez-Bautista und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gerontopole, Clinical and Geroscience Research, Toulouse University Hospital, WHO Collaborating Center for Frailty, and Geriatric Training, Toulouse,…. Hauptthemen laut MEDLINE: Inflammation, Cognition, Alzheimer Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Université Toulouse III - Paul Sabatier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to evaluate the association of systemic inflammation measured by plasma biomarkers with the change in cognitive function among participants from the Multidomain Alzheimer Preventive Trial (MAPT) exposed to the multidomain intervention (MI). Secondary analysis of the MAPT longitudinal data. MAPT is a randomized, placebo-controlled trial with 3 interventional groups (omega-3 only, MI only, omega-3 plus MI) and a control group. We tested the association of the change in cognitive function with inflammatory biomarkers (tumoral necrosis factor receptor-1 (TNFR1), monocyte chemoattractant protein-1 (MCP1), Growth Differentiation Factor-15 (GDF15), Interleukin-6 (IL6) and C reactive protein (CRP)) using mixed-effects models. A subgroup analysis was performed in those exposed to the MI. The response to the MI was defined as the change in the composite cognitive score over the 2-year clinical follow-up period. by modeling the response to the intervention and identifying “good responders”, i.e., those in the 5th quintile of response at the end of the intervention period (2 years after the measurement of inflammatory markers). We included 1,527 participants (mean age 75.3, SD = 4.4; 64% female). Higher levels of GDF15 and TNFR1 were associated with a worse trajectory in the cognitive composite score in adjusted models. "Good responders" had an estimated mean change in the composite score of 0.051 (SD 0.062) over two years of intervention, compared to -0.136 (SD = 0.111) for the "not-good responders". Higher IL6 levels were associated with a decreased likelihood of being a "good responder" (OR = 0.22, p = 0.018, 95% CI 0.06; 0.78), with similar results for CRP (OR = 0.48, p = 0.009, 95% CI 0.28; 0.84). Higher inflammation was associated with a worse cognitive trajectory among nondemented participants and a lower likelihood of being classified as a "good responder" in those receiving a MI. Further confirmation of these findings could lead to the use of systemic inflammation as inclusion or stratification criteria in prevention trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammationCognitionAlzheimer DiseaseHumansFemaleBiomarkersMaleAgedLongitudinal StudiesC-Reactive ProteinInterleukin-6Receptors, Tumor Necrosis Factor, Type IAged, 80 and overGrowth Differentiation Factor 15Chemokine CCL2

Stichwörter der Autor:innen

Alzheimer’s diseaseCognitive composite scoreGDF-15InflammationMultidomain intervention

Substanzen

BiomarkersC-Reactive ProteinInterleukin-6Receptors, Tumor Necrosis Factor, Type IGrowth Differentiation Factor 15Chemokine CCL2

Autor:innen und Institutionen

  • Gerontopole, Clinical and Geroscience Research, Toulouse University Hospital, WHO Collaborating Center for Frailty, and Geriatric Training, Toulouse, France. emmanuel.scout@gmail.com.
  • Maintain Aging Research Team, Centre d'Epidémiologie Et de Recherche en Santé Des POPulations, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France. emmanuel.scout@gmail.com.
  • IHU HealthAge, Toulouse, France. emmanuel.scout@gmail.com.
  • Gerontopole, Clinical and Geroscience Research, Toulouse University Hospital, WHO Collaborating Center for Frailty, and Geriatric Training, Toulouse, France.
  • Maintain Aging Research Team, Centre d'Epidémiologie Et de Recherche en Santé Des POPulations, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France.
  • IHU HealthAge, Toulouse, France.

ORCID-Profile: Emmanuel Gonzalez-Bautista, Gabor Abellan van Kan

Förderung

  • Université Toulouse III - Paul Sabatier

Zitieren

APA

Gonzalez-Bautista, E., Soto, M., Abellan van Kan, G., & Delrieu, J. (2025). Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study. GeroScience. https://doi.org/10.1007/s11357-024-01497-2

Vancouver

Gonzalez-Bautista E, Soto M, Abellan van Kan G, Delrieu J. Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study. GeroScience. 2025. doi:10.1007/s11357-024-01497-2

BibTeX
@article{GonzalezBautista2025,
  author = {Gonzalez-Bautista, Emmanuel and Soto, Maria and Abellan van Kan, Gabor and Delrieu, Julien},
  title = {Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study},
  journal = {GeroScience},
  year = {2025},
  doi = {10.1007/s11357-024-01497-2}
}
Kostenlos starten →